DAPAGLIFLOZIN IN PATIENTS WITH CHF IN COMBINATION WITH POST-COVID SYNDROME

Osmanova A. V., Kudaev M. T., Kallaeva A. I., Ataeva Z. N., Guseinova R. K., Gadzhieva T. A., Ezilyaeva M. R.

We studied the effectiveness of Dapagliflozin in patients with CHF with systolic dysfunction (EF less than 45%), suffering from post-Covid syndrome, and with previous SARS-CoV-2 infection. General clinical and biochemical research methods, a coagulogram were carried out, the dynamics of acute-phase parameters and the dynamics of the content of natriuretic peptides in the plasma of patients were monitored. The virus was detected at least once by the presence of SARS-CoV-2 RNA in a smear from the nasopharynx and oropharynx using polymerase chain reaction. ECG was recorded and ECG Holter monitoring was performed. Indicators of central and intracardiac hemodynamics were determined using a Voluson E 10 ultrasound scanning system using standard methods. QOL was determined using the Kansas City Cardiomyopathy Questionnaire (KCCQ). In each case, the psycho-emotional state was studied according to the Khanin questionnaire, self-assessment of the state - according to the VAS scale (Visual Analog Scale), TKFN - using the 6-minute walk method proposed by V. Bittner et al. In 1993. The data obtained indicate that the addition of dapagliflozin to the complex therapy of patients with CHF with post-Covid syndrome leads to a significant improvement in the quality of life and prognosis of life of patients with previous systolic dysfunction and an increase in their survival.

Keywords:dapagliflozin, post-Covid syndrome, chronic heart failure